

CURRICULUM VITAE

Philippos Apolinario Costa, MD

Version Date: 8/8/2026

Contact Information:

Address 35 Park Street
New Haven, CT 06511
Phone: 1 (305) 988-0298
Email: philippos.costa@yale.edu

School: Yale School of Medicine

Education:

01/2010 - 01/2016 MD, Universidade Federal do Vale do São Francisco, Medicine, Petrolina, PE, Brazil
07/2023 - 07/2025 MS, Yale, Internal Medicine, New Haven, CT

Career/Academic Appointments:

03/2016 - 03/2018 Internal Medicine Resident, Internal Medicine, Universidade Federal de Uberlândia:, Uberlândia, MG, Brazil
03/2018 - 12/2018 Hospitalist, Oncology, Hospital do Câncer de Uberlândia, Uberlândia, MG, Brazil
01/2019 - 06/2019 Intensivist, Critical Care, Hospital Neurocárdio, Petrolina, PE, Brazil
06/2019 - 06/2022 Internal Medicine Resident, Internal Medicine, University of Miami, Miami, FL
07/2022 - 06/2025 Oncology Fellow, Oncology, Yale Universit, New Haven, CT
07/2025 - 06/2028 Assistant Professor, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2022 - Present Scientific-Advisor, Medical Oncology, Associação Tumor Desmoide Brasil, São Paulo, SP, Brazil

Board Certification:

2022 - 2026 AB of Internal Medicine, Internal Medicine

Professional Honors & Recognition:

International/National/Regional

2022 The Vanessa Blumer Research Scholar Award

Grants/Clinical Trials History:

Current Clinical Trials

Agencies: Southwest Oncology Group (SWOG)

I.D.#: 2000020739

Title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

P.I.: Philippos Costa

Role: Principal Investigator

Percent effort: N/A

Total costs: -

Project period: 04/11/2017 - ongoing

Agencies: National Cancer Institute (NCI)

I.D.#: 2000021392

Title: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

P.I.: Philippos Costa

Role: Principal Investigator

Percent effort: N/A

Total costs: -

Project period: 07/21/2017 - ongoing

Agencies: Alliance for Clinical Trials in Oncology

I.D.#: 2000030441

Title: A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

P.I.: Philippos Costa

Role: Principal Investigator

Percent effort: N/A

Total costs: -

Project period: 04/29/2021 - ongoing

Agencies: Eastern Coop Onc Group-American College Radiology Imaging Netwk(ECOG-ACRIN)

I.D.#: 2000035965

Title: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)

P.I.: Philippos Costa

Role: Principal Investigator

Percent effort: N/A

Total costs: -

Project period: 11/30/2023 - ongoing

Agencies: National Cancer Institute (NCI)
 I.D.#: 2000036828
 Title: Testing Ipilimumab and Nivolumab Combination with or without Cabozantinib in People $\geq$ 18 Years Old with Advanced Soft Tissue Sarcoma
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 08/06/2024 - ongoing

Agencies: Inhibrx, Inc.
 I.D.#: 2000038416
 Title: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/07/2024 - ongoing

Agencies: Institut de Recherches Internationales Servier (I.R.I.S.)
 I.D.#: 2000037892
 Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants $\geq$ 18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/30/2024 - ongoing

Agencies: National Cancer Institute (NCI)
 I.D.#: 2000039444
 Title: Testing Atezolizumab with Selinexor in People $\geq$ 12 Years Old with Alveolar Soft Part Sarcoma, The AXIOM Trial
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/05/2025 - ongoing

Agencies: Kura Oncology, Inc.
 I.D.#: 2000039616
 Title: A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 04/18/2025 - ongoing

Agencies: Eastern Cooperative Oncology Group (ECOG)
 I.D.#: 2000040550
 Title: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 07/28/2025 - ongoing

Agencies: Cogent Biosciences, Inc.
 I.D.#: 2000042130
 Title: Expanded Access to Bezucastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/24/2026 - ongoing

Agencies: GlaxoSmithKline, LLC
 I.D.#: 2000041392
 Title: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -

Project period: 02/25/2026 - ongoing

Agencies: Zai Laboratory
 I.D.#: 2000042336
 Title: An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/04/2026 - ongoing

Pending Clinical Trials

Agencies: Pfizer Inc., U.S. Pharmaceuticals Group
 I.D.#: 2000042838
 Title: C6321001: A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-08032562 in Participants with Advanced or Metastatic Solid Tumors [WCG]
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -

Agencies: -
 I.D.#: 2000043033
 Title: A Prospective Multi-Institutional Study of Circulating Tumor DNA in Sarcoma
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -

Agencies: GlaxoSmithKline, LLC
 I.D.#: 2000043179
 Title: 306293: A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Advarra IRB]
 P.I.: Philippos Costa
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -

Agencies: Intensity Therapeutics, Inc.

I.D.#: 2000038189
Title: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas (INVINCIBLE-3)
(INVINCIBLE-3)
P.I.: Philippos Costa
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 01/03/2025 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. "Clinical Trials in Desmoid Tumors". Associação Tumor Desmoide Brasil, 3º Setembro Consciente, São Paulo, SP, September 2022. (Lecture)
2. "OsteoBites | Zanzalintinib in Osteosarcoma Balancing Disease Control and Quality of Life". Osteobites, MIB website, and Youtube, April 2026. (Oral Presentation)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. Costa PA, Reis WG, Portela GJS, Alencar KMSA. Penile Cancer: Incidence, clinical and epidemiological profile at the Center of Oncology Dr. Muccini in Petrolina-Pe. Sociedade Brasileira de Clínica Médica (SBCM), 13 meeting of the Brazilian Internal Medicine Society, Recife, PE, September 2015. (Poster Presentation)
2. Costa PA, Reis WG, Portela GJS, Alencar KMSA. Melanoma a Retrospective analysis in Center of Oncology Dr. Muccini in Petrolina-Pe 2007-2011. Sociedade Brasileira de Clínica Médica (SBCM), 13 meeting of the Brazilian Internal Medicine Society, Recife, PE, September 2015. (Poster Presentation)
3. Costa PA, Marbin S, Costa BMLA, Espejo-Freire A, Saul E, Barreto-Coelho P, Allen A, Goel N, Subhawong TK, D'Amato G, Trent JC. A Non-Random Association of Breast Implants and the Formation of Desmoid Tumors. Connective Tissue Oncology Society, 2020 CTOS Annual Meeting, Boca Raton, FL, November 2020. (Poster Presentation)
4. Jonczak EE, Hana C, Espejo A, Arshad J, Costa PA, Barreto-Coelho P, Sdrimas K, Valdes B, D'Amato G, Trent JC. Updated analysis of genetic alterations in sarcoma patients of hispanic and non-hispanic ethnicity: analysis of 174 patients, a single institution experience. Connective Tissue Oncology Society, 2020 CTOS Annual Meeting, Boca Raton, FL, November 2020. (Poster Presentation)
5. Hakim MO, Costa PA, Perez JAD, Behtaj M, Montgomery EA, Torres JV, Rosenber AE. Dedifferentiated Chondrosarcoma: How much Really Counts?. United States and Canadian Academy of Pathology, USCAP 2021, Palm Springs, CA, March 2021. (Oral Presentation)
6. Bialick S, Valdes B, Costa PA, Barreto-Coelho P, Espejo-Freire A, D'Amato G, Jonczak E, Dhir A, Rosenber A, Forghani I, Trent JC. Sarcoma as an extracolonic malignancy of lynch syndrome.

- Connective Tissue Oncology Society, 2021 CTOS Annual Meeting, Virtual, November 2021. (Poster Presentation)
7. Costa PA, Valdes B, Barreto-Coelho P, Espejo-Freire A, D'Amato G, Jonczak E, Sbhawong T, Trent JC. Ripretinib Dose Escalation in Advanced Gastrointestinal Stromal Tumor: A Real-world Data.. Connective Tissue Oncology Society, 2021 CTOS Annual Meeting, Virtual, November 2021. (Poster Presentation)
 8. Freire APE, Elliot A, Akgun Y, Alasfour M, Rosenberg A, Diaz-Perez JA, Subhawong T, Arshad J, Korn WM, Dizon DS, Mehren M, Khusman M, Hussei AM, Leu K, Trent JC. Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients.. American Society of Clinical Oncology, American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 2022. (Poster Presentation)
 9. Costa PA, Arora A, Tan H, Fernandez Y, Barreto-Coelho P, Bialick S, Espejo A, Jonczak E, D'Amato G, Deshpande H, Subhawong T, Trent JC. Comparative Effectiveness of Systemic Treatments in Desmoid Tumors. Desmoid Tumor Research Foundation, 2022 DTRF International Desmoid Tumor Research Workshop, Virtual, September 2022. (Oral Presentation)
 10. **Costa PA.** Sorafenib treatment duration in desmoid tumors.. American Society of Clinical Oncology , American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2024. (Poster Presentation)
 11. **Costa PA,** Olino K, Frey A, Ishizuka J. SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2024. (Poster Presentation)

Professional Service:

Peer Review Groups/Grant Study Sections

2021 - Present Reviewer, GIST Journal

Advisory Boards

2022 - Present Advisor, Scientific and medical advisory board, Brazilian Sarcoma Group, Provide scientific and clinical guidance to a Brazilian patient advocacy organization focused on sarcoma and desmoid tumors, supporting education, patient resources, and initiatives to improve access to specialized care.

Journal Services

Editorial boards

2026 - Present Editorial Board Member, Journal of Clinical Oncology Oncology Advances, Sarcoma Editorial Board Member

Professional Organizations

American College of Physicians (ACP)

2018 - Present Member, American College of Physicians (ACP)

American Society of Clinical Oncology (ASCO)

2018 - Present Member, American Society of Clinical Oncology (ASCO)

Connective Tissue Oncology Society (CTOS)

2019 - Present Member, Connective Tissue Oncology Society (CTOS)

Sociedade Brasileira de Oncologia Clínica (SBOC)

2018 - Present Member, Sociedade Brasileira de Oncologia Clínica (SBOC)

Yale University / Hospital System

Medical School

2012 - 2014 Treasurer, Universidade Federal do Vale do São Francisco, Student Representative Council

2022 Research Committee Member, University of Miami, Research Committee for the Hematology and Oncology Resident track

Public Service / Media Presence

Media Presence

2022 - Present Researcher, Managed Health Care, Featured in magazine article entitled “Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy” based on the work “Prevalence of Targetable Mutations in Black Patients”

2026 - Present Interviewee, Oncolive, Answering Common Questions About Chondrosarcoma Diagnosis and Management

Bibliography:

Peer-Reviewed Original Research

1. Ferreira Junior E, **Apolinario Costa P**, Freire Golveia Silveira L, Valois Vieira R, Lima Martins Soares H, Menon Loureiro B, Pertile Salvioni N, Coelho Ferreira Rocha J. Localized pancreatic Castleman disease presenting with extrahepatic dilatation of bile ducts: A case report and review of published cases. International Journal Of Surgery Case Reports 2018, 54: 28-33. [PMID: 30513495](#), [PMCID: PMC6279997](#), [DOI: 10.1016/j.ijscr.2018.11.006](#).
2. **Costa P**, Reis W, Loureiro B, Ferreira E, Rocha J, Alencar K. Tumor Desmoplásico de Pequenas Células Redondas: Relato de Caso. Revista Brasileira De Cancerologia 2018, 64: 575-579. [DOI: 10.32635/2176-9745.rbc.2018v64n4.208](#).
3. Ferreira Junior E, **Costa P**, Silveira L, Almeida L, Salvioni N, Loureiro B. Giant bullous emphysema mistaken for traumatic pneumothorax. International Journal Of Surgery Case Reports 2019, 56: 50-54. [PMID: 30826593](#), [PMCID: PMC6402233](#), [DOI: 10.1016/j.ijscr.2019.02.005](#).
4. Ferreira Junior E, **Costa P**, Freire Golveia Silveira L, Pertile Salvioni N, Loureiro B, Lodi Peres S, Pereira T. Transhiatal esophagectomy with gastric pull-up, pyloric exclusion and Roux-en-Y gastroenterostomy for the management of esophageal caustic injury. International Journal Of

- Surgery Case Reports 2019, 56: 66-69. [PMID: 30831510](#), [PMCID: PMC6403175](#), [DOI: 10.1016/j.ijscr.2019.02.006](#).
5. **Costa P**, Needelman B, Tjendra Y, Hoffman J. High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass. BMJ Case Reports 2020, 13: e235451. [PMID: 32843454](#), [PMCID: PMC7449310](#), [DOI: 10.1136/bcr-2020-235451](#).
 6. **Costa P**, Costa B, Milikowski C, St Onge J. Acute generalised exanthematous pustulosis associated with shock. BMJ Case Reports 2020, 13: e235846. [PMID: 33127730](#), [PMCID: PMC7604797](#), [DOI: 10.1136/bcr-2020-235846](#).
 7. Costa PA, Hana CKA, Chakravarthy N, Skryd AF, Valdes BN, Barreto-Coelho P, Minjares RO, Espejo-Freire A, Hakim MO, Jonczak E, Subhawong T, Livingstone A, Trent JC, D'Amato GZ. Dose Escalation of Ripretinib can Lead to Response in Advanced Gastrointestinal Stromal Tumors Refractory to the Standard Dose: A Report of Two Cases. Gastrointestinal Stromal Tumor. DOI: 10.21037/gist-21-1
 8. Barreto-Coelho P, **Costa P**, Espejo-Freire A, Jonczak E, D'Amato G, Trent J. Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances. TouchREVIEWS In Oncology & Haematology 2021, 17: 18. [DOI: 10.17925/ohr.2021.17.1.18](#).
 9. **Costa P**, Hana C, Balaji N, Skryd A, Valdes B, Minjares R, Barreto-Coelho P, Espejo-Freire A, Hakim M, Jonczak E, Subhawong T, Livingstone A, Trent J, D'Amato G. Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. Gastrointestinal Stromal Tumor 2021, 4: 1-1. [DOI: 10.21037/gist-21-1](#).
 10. **Costa P**, Costa B, Rozenbaum G, Barreto-Coelho P. Anti-Ma paraneoplastic opsoclonus–myoclonus syndrome. BMJ Case Reports 2021, 14: e243136. [PMID: 33975854](#), [PMCID: PMC8117984](#), [DOI: 10.1136/bcr-2021-243136](#).
 11. **Costa P**, Marbin S, Costa B, Espejo-Freire A, Saul E, Barreto-Coelho P, Allen A, Hakim M, Goel N, D'Amato G, Subhawong T, Trent J. A nonrandom association of breast implants and the formation of desmoid tumors. The Breast Journal 2021, 27: 768-775. [PMID: 34453383](#), [DOI: 10.1111/tbj.14276](#).
 12. Freire A, Elliott A, Rosenberg A, **Costa P**, Barreto-Coelho P, Jonczak E, D'Amato G, Subhawong T, Arshad J, Diaz-Perez J, Korn W, Oberley M, Magee D, Dizon D, von Mehren M, Khushman M, Hussein A, Leu K, Trent J. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. Cancers 2021, 13: 4816. [PMID: 34638300](#), [PMCID: PMC8507700](#), [DOI: 10.3390/cancers13194816](#).
 13. Barreto-Coelho P, Rosenberg A, Subhawong T, **Costa P**, Espejo-Freire A, Bialick S, Jonczak E, Trent J, D'Amato G. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precision Oncology 2022, 6: e2100336. [PMID: 35108034](#), [DOI: 10.1200/po.21.00336](#).
 14. Minjares R, **Costa P**, Montoya-Cerrillo D, Aguirre L. Primary jejunal gastrointestinal stromal tumor in a patient with phakomatosis: a case report of an uncommon source of massive gastrointestinal hemorrhage. Gastrointestinal Stromal Tumor 2022, 5: 2-2. [DOI: 10.21037/gist-21-13](#).
 15. O'Neil D, Martei Y, Crew K, Castillo B, **Costa P**, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni M. Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open 2023, 6: e2346223. [PMID: 38051529](#), [PMCID: PMC10698616](#), [DOI: 10.1001/jamanetworkopen.2023.46223](#).
 16. Souza F, D'Amato G, Jonczak E, **Costa P**, Trent J, Rosenberg A, Yechieli R, Temple H, Pattany P, Subhawong T. MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a

- quantitative imaging biomarker of tumor response: preliminary results. *Frontiers In Oncology* 2023, 13: 1286807. [PMID: 38188297](#), [PMCID: PMC10766853](#), [DOI: 10.3389/fonc.2023.1286807](#).
17. **Costa P**, Tse D, Benedetto P. Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. *The Oncologist* 2024, 29: 263-269. [PMID: 38227581](#), [PMCID: PMC10911902](#), [DOI: 10.1093/oncolo/oyad346](#).
18. Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, **Costa P**. Real-world experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSarCC multi-center study. *European Journal Of Cancer* 2024, 205: 114119. [PMID: 38759389](#), [DOI: 10.1016/j.ejca.2024.114119](#).
19. **Costa P**, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D'Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors. *Cancer* 2024, 131: e35647. [PMID: 39543805](#), [DOI: 10.1002/cncr.35647](#).
20. **Costa P**, Menezes C, David B, Garofalo G, Barbieri L, Campos F. Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association. *Therapeutic Advances In Medical Oncology* 2025, 17: 17588359241309827. [PMID: 39801613](#), [PMCID: PMC11719451](#), [DOI: 10.1177/17588359241309827](#).
21. Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, **Costa P**, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. *Surgical Oncology Insight* 2025, 2: 100120. [DOI: 10.1016/j.soi.2024.100120](#).
22. Hardy N, Frej K, Nkansah R, Olino K, Deshpande H, Ma X, Trent J, **Costa P**. Twenty-five years without progress: The enduring challenge of soft tissue sarcomas. *Cancer* 2025, 131: e35906. [PMID: 40396557](#), [DOI: 10.1002/cncr.35906](#).
23. Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire A, Coelho P, **Costa P**, D'Amato G, Jonczak E, Trent J, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. *Cancers* 2025, 17: 1962. [PMID: 40563612](#), [PMCID: PMC12191036](#), [DOI: 10.3390/cancers17121962](#).
24. **Costa P**, Hardy N, LoRusso P. PALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity. *BMJ Case Reports* 2025, 18: e266362. [PMID: 40750108](#), [DOI: 10.1136/bcr-2025-266362](#).
25. Raja A, **Costa P**, Junejo M. Kaposi sarcoma incidence and mortality trends and disparities in the United States. *Infectious Agents And Cancer* 2025, 20: 80. [PMID: 41189007](#), [PMCID: PMC12584236](#), [DOI: 10.1186/s13027-025-00710-x](#).
26. Aleixo G, Hartner L, Diamond M, Wong W, Allen J, Yi I, **Costa P**, Lefler D. Liposomal Versus Conventional Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas: Observational Multi-Institutional Cohort of 8.5-Year Experience. *JCO Oncology Practice* 2026, op2600132. [PMID: 41990299](#), [DOI: 10.1200/op-26-00132](#).
27. Govindan A, **Costa P**, Feinn R, Deshpande H. Trends in metastatic thyroid cancer survival from 1992 to 2022: a SEER database analysis. *Endocrine Oncology* 2026, 6: e250086. [PMID: 42181031](#), [PMCID: PMC13193066](#), [DOI: 10.1530/eo-25-0086](#).

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Barreto-Coelho P., Costa PA, Espejo-Freire A., Jonczak E., D'Amato G., Trent J.C. Advanced and Metastatic GIST: Review of Current Knowledge and Latest Advances 2021; touchONCOLOGY.
2. **Costa P**, Saul E, Paul Y, Iyer S, da Silva L, Tamariz L, Lopes G. Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice 2021, 17: e629-e636. [PMID: 33974815](#), [DOI: 10.1200/op.20.00961](#).
3. Arshad J, **Costa P**, Barreto-Coelho P, Valdes B, Trent J. Immunotherapy Strategies for Gastrointestinal Stromal Tumor. Cancers 2021, 13: 3525. [PMID: 34298737](#), [PMCID: PMC8306810](#), [DOI: 10.3390/cancers13143525](#).
4. Karigyo C, Pessoa B, Nicacio S, Terwilliger E, **Costa P**, dos Santos P, Ernani V, Seetharam M, Murakami A, Batalini F. Cardiac Tumors: Review. Brazilian Journal Of Cardiovascular Surgery 2024, 39: e20230405. [PMID: 39038269](#), [PMCID: PMC11262154](#), [DOI: 10.21470/1678-9741-2023-0405](#).
5. Pfaff M, **Costa P**, Tang H, Sailo B, Sharma A, Ahuja N. Decoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma. Cancers 2025, 17: 2610. [PMID: 40867239](#), [PMCID: PMC12384543](#), [DOI: 10.3390/cancers17162610](#).
6. Spricido I, Bignoto T, Beal J, Silva D, **Costa P**, Moura F, Teixeira F, Filippi R, Jesus-Garcia R, Pestana R. Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: a perspective on evidence gaps. ESMO Rare Cancers 2026, 6: 100131. [DOI: 10.1016/j.esmorc.2026.100131](#).

Peer-Reviewed Case Reports and Technical Notes

1. Costa PA, Reis WG, Loureiro BM, Ferreira Junior EG, Rocha JRFC, Alencar KMSA. Revista Brasileira De Cancerologia, 2018, Dec; 64(4), 573-577.
2. Minjares RO, Aguirre LE, Costa PA, Montoya-Cerrillo DM, Goldberg DS. Primary Jejunal GIST in a Patient with Phakomatosis: An Atypical Source of Massive Gastrointestinal Hemorrhage Associated with RASopathy. Gastrointestinal Stromal Tumor 2022. doi: 10.21037/gist-21-13

Commentaries, Editorials and Letters

1. **Costa P**, Espejo-Freire A, Fan K, Albini T, Pongas G. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. Leukemia & Lymphoma 2021, 63: 239-242. [PMID: 34514943](#), [DOI: 10.1080/10428194.2021.1978090](#).
2. Yan C, **Costa P**, Wu Y. Acute pancreatitis from a delayed haemolytic transfusion reaction. Transfusion Medicine 2022, 32: 522-524. [PMID: 36056461](#), [DOI: 10.1111/tme.12912](#).
3. Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, **Costa P**. Corrigendum to “Real-world experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSarCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]. European Journal Of Cancer 2024, 208: 114221. [PMID: 38981738](#), [DOI: 10.1016/j.ejca.2024.114221](#).
4. **Costa P**, Tse D, Benedetto P. In Reply to: “Response to intra-arterial chemotherapy in patients with adenoid cystic carcinoma of lacrimal gland”. The Oncologist 2026, 31: oyag087. [PMID: 41955416](#), [PMCID: PMC13091707](#), [DOI: 10.1093/oncolo/oyag087](#).